Funded by LUNGevity Foundation in partnership with Goldman Philanthropic Partnerships
Sreenath V. Sharma, PhD
Massachusetts General Hospital
Boston
By modeling acquired resistance to gefitinib and erlotinib in the laboratory using a non-small cell lung cancer (NSCLC) cell line that is sensitive to these drugs, Dr. Sharma hopes to uncover the molecular basis for acquired resistance of NSCLC to these targeted therapeutics as well as clues to overcoming this resistance.